News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Haemonetics Corporation (HAE) Effects 2-For-1 Split of Its Common Stock


12/3/2012 9:23:38 AM

BRAINTREE, Mass., Dec. 3, 2012 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) has effected a 2-for-1 split of all shares of its common stock, in the form of a 100 percent stock dividend. Each outstanding share of the Company's pre-split common stock, including shares subject to outstanding stock options and shares available for grant under the Company's equity incentive plans, was split into two shares effective 5:00pm Eastern Time on November 30, 2012.

(Logo: http://photos.prnewswire.com/prnh/20120206/NE47232LOGO)

The shares of common stock issued pursuant to the split will be delivered to the Company's stockholders of record as of the record date, November 9, 2012. The split affected all stockholders uniformly and did not alter any stockholder's ownership percentage. The Company's common stock will begin trading on a post-split basis on the New York Stock Exchange at the opening of trading today, December 3, 2012.

The Company expects that this split will make its shares more accessible and increase its shareholder base, thereby improving its market liquidity. Additionally this stock split reflects the Company's confidence in its strength and ability to continue to generate long term growth and financial performance.

Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing innovative blood management solutions for our customers. Together, our devices and consumables, information technology platforms, and consulting services deliver a suite of business solutions to help our customers improve clinical outcomes and reduce the cost of healthcare for blood collectors, hospitals, and patients around the world. Our technologies address important medical markets: blood and plasma component collection, the surgical suite, and hospital transfusion services. To learn more about Haemonetics, visit our web site at http://www.haemonetics.com.

CONTACT:
Gerry Gould, VP-Investor Relations
Tel. (781) 356-9402
gerry.gould@haemonetics.com
Alt. (781) 356-9613

SOURCE Haemonetics Corporation


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES